Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
India · Delayed Price · Currency is INR | Market Cap | 1.05T |
| Revenue (ttm) | 342.15B |
| Net Income (ttm) | 58.62B |
| Shares Out | n/a |
| EPS (ttm) | 70.30 |
| PE Ratio | 17.84 |
| Forward PE | 21.32 |
| Dividend | 8.00 (0.64%) |
| Ex-Dividend Date | Jul 10, 2025 |
| Volume | 1,215,477 |
| Average Volume | 985,191 |
| Open | 1,252.60 |
| Previous Close | 1,256.20 |
| Day's Range | 1,240.00 - 1,265.00 |
| 52-Week Range | 1,020.00 - 1,405.90 |
| Beta | 0.35 |
| RSI | 40.69 |
| Earnings Date | Jan 21, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]
Financial Performance
In 2024, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial StatementsNews
Pharma generics: Semaglutide patent expiry to open Rs 50bn opportunity; Indian players eye FY27 boost
Semaglutide patent expiries in India, Canada, and Brazil are poised to unlock over Rs 50 billion in revenue for generic drugmakers within 12-15 months. Indian companies like Alkem, Dr Reddy's, and Sun...
Dr Reddy’s shares fall nearly 2% today as JPMorgan flags USFDA setback, cuts target to Rs 1,170
Friday, Jan 2: Shares of Dr Reddy’s Laboratories slipped nearly 2% in Friday’s session after JPMorgan reiterated its ‘Underweight’ rating...
Dr. Reddy’s Laboratories in focus today as JPMorgan flags regulatory setback
Shares of Dr. Reddy’s Laboratories are in focus today, Friday, after JPMorgan maintained an ‘Underweight’ rating on the stock with...
Nifty 50 top losers today, January 1: ITC, Dr. Reddy’s, Bajaj Finance, Tata Consumer Products, ONGC, Cipla and more
Indian equity benchmarks ended the first trading session of 2026 on a mixed note as markets witnessed intraday volatility. The...
Dr Reddy, Cipla, Sun Pharma and other stocks in focus today as Govt bans high-dose Nimesulide formulations
Shares of several pharmaceutical companies are likely to remain in focus after the Ministry of Health and Family Welfare (MoHFW)...
Nifty 50 top losers today, December 24: IndiGo, Dr. Reddy’s, Wipro, Adani Enterprises, HDFC Life, Tata Motors PV and more
Indian equity benchmarks ended marginally lower in a highly volatile session on December 24, with selling pressure visible across several...
Dr Reddy’s Laboratories shares in focus as company’s semaglutide not approved in Canada – Know More
Shares of Dr Reddy’s Laboratories are in focus after a Bloomberg report said that the company’s generic semaglutide has not...
Dr Reddy’s semaglutide not approved in Canada as Health Canada flags regulatory gaps: Report
Dr Reddy’s Laboratories has not received regulatory approval for its semaglutide drug in Canada, with Health Canada indicating that the...
Dr. Reddy’s Laboratories receives five observations following USFDA inspection at Srikakulam facility
Dr. Reddy’s Laboratories has announced that the United States Food & Drug Administration (USFDA) has completed a comprehensive GMP and...
Dr. Reddy’s Laboratories announces SBTi-approved Net Zero targets for FY2045
Dr. Reddy’s Laboratories Ltd. has formally announced its Net Zero commitments after receiving approval for both its near-term and long-term...
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.
Dr. Reddy’s Laboratories enters strategic collaboration with Immutep SAS for exclusive licensing of eftilagimod alfa
Dr. Reddy’s Laboratories has entered into a major strategic collaboration with Immutep Limited, marking an important step in expanding access...
JSW Steel, Kotak Mahindra & more: Top stocks to buy today — Check list
Brokerage firms are bullish on JSW Steel and Tata Consumer Products, forecasting significant growth. Aurobindo Pharma shows strong momentum. Kotak Mahindra Bank might acquire IDBI Bank, a move that co...
Dr Reddys, Titan & more: Top stocks to buy on December 3 — Check list
Leading financial institutions are bullish on select Indian stocks. HSBC recommends Dr Reddy's Labs for its semaglutide prospects, while Goldman Sachs sees strong growth for Titan's jewellery and othe...
Dr Reddy’s can make Novo’s weight loss drug, rules HC
India Business News: NEW DELHI: In a significant development in the blockbuster weight loss drug space, Delhi High Court has allowed Dr Reddy’s Labs to manufacture and exp.
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
BANGALORE, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112.
Nifty 50 top gainers today, December 2: Asian Paints, Dr. Reddy’s Laboratories, Maruti Suzuki India, Bharti Airtel and more
Indian equity benchmarks ended in the red on December 2, with both major indices slipping amid broad-based weakness. The Sensex...
Dr. Reddy’s Laboratories arm Aurigene Oncology receives GST appellate order
Dr. Reddy’s Laboratories informed the exchanges that its wholly owned subsidiary Aurigene Oncology Limited has received an order from the...
Biosimilar push: Dr Reddy’s gets EU nod for denosumab copy; Prolia, Xgeva rivals set for rollout
Dr. Reddy's Laboratories has achieved a significant regulatory win with the European Commission approving AVT03, its biosimilar for osteoporosis treatment. This authorization extends across all EU nat...
Dr. Reddy’s Laboratories receives European Commission approval for AVT03
Dr. Reddy’s Laboratories Ltd. announced that the European Commission (EC) has granted marketing authorization for AVT03, a biosimilar to Prolia®...
Dr. Reddy's Laboratories Breaks Above 200-Day Moving Average - Bullish for RDY
In trading on Wednesday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $14.08, changing hands as high as $14.10 per share. Dr. Reddy's Laboratorie...
Dr. Reddy’s API facility clears USFDA GMP inspection with zero observations
Dr. Reddy’s Laboratories announced that the US Food & Drug Administration (USFDA) has completed a GMP inspection at its API...
How Hackers Duped Drugmakers Dr Reddy's, Group Pharmaceuticals Of Rs 2 Crore
In a major case of cyber fraud, a sum of Rs 2.16 crore has been siphoned off after fraudsters hacked email communications between Bengaluru-based Group Pharmaceuticals Ltd and Dr. Reddy's Laboratories...
Dr. Reddy's Laboratories Becomes Oversold (RDY)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Dr. Reddy’s Laboratories shares fall over 4% after delay in Semaglutide approval in Canada
Dr. Reddy’s Laboratories’ shares fell more than 4% in early trade on Thursday, October 30, after the company announced a...